Phase 1 N=30 Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
Ricin
Primary: Number of Vaccinated Subjects Any Averse Events and by Location and Severity — 10; 10; 9; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=4 Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
Ricin Poisoning
Primary: Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity. — 0; 3; 3; 2 participants
N/A N=102 European Survey: Risk of Cyanide Poisoning in Smoke Inhalation
Smoke Inhalation Patients
Primary: Overall Survival After 24 Hours — 96 participants
N/A N=10 Botulinum Toxin in the Treatment of Raynaud's
Raynaud's Syndrome
Primary: Mean Digital Temperature Difference From Baseline — 1.30 Celsius
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants